Tech's hottest IPOs of the year, including Beyond Meat and Zoom, dropped on Monday, falling more than the broader market.Technologyread more
Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
While earnings usually come in substantially ahead of expectations — as much as 4 or 5 percentage points is not unusual — the downward direction in the outlook doesn't speak...Earningsread more
"We missed being the dominant mobile operating system by a very tiny amount. We were distracted during our antitrust trial. We didn't assign the best people to do the work,"...Technologyread more
PatientsLikeMe was bought by UnitedHealth following a review by Trump's Treasury Department, which scrutinized the start-up because it's backed by Chinese cash.Technologyread more
Some traders think the energy rally is about to wane, despite the sector being one of June's big winners.ETF Edgeread more
Stocks with this one feature are poised to crush the market after a rate cut, according to Goldman Sachs.Marketsread more
An Air Canada passenger traveling to Toronto from a weekend in Quebec City found herself stranded alone on the tarmac and in the dark, in what she described as a "nightmare."Airlinesread more
When Victoria's Secret exited the swimsuit business in 2016, it opened the floodgates for start-ups to conquer that market.Retailread more
U.K. online bank Monzo raised $144 million in a fresh round of funding led by the U.S. start-up accelerator Y Combinator.Technologyread more
stock rocketed up more than 70 percent in midday trading Monday after an FDA panel voted in favor of the company's primary drug under development.
The majority of an FDA advisory committee voted "yes" when asked whether data support the safety of Dynavax's Heplisav.
"[The] panel vote is a major win for Dynavax," J.P. Morgan analyst Anupam Rama wrote in a note. "We now believe that Heplisav has a high probability of approval by the August 10th [FDA review deadline]."
The immunotherapy company is developing Heplisav as a hepatitis B vaccine treatment for adults. Heplisav could become the standard treatment for the viral liver infection, Rama said, because Dynavax's drug has an easier dosing schedule than competitor GlaxoSmithKline's Engerix-B.
The shares rose as high as $17.20 at one point Monday, an 86 percent pop, and were last up 74 percent to $16.15.
Two previous FDA reviews of Heplisav rejected the vaccine, citing unresolved safety concerns.
Heplisav aims to boost patients' immune systems in response to hepatitis B, an incurable disease which can lead to liver cancer and death.
While the FDA committee's review said Heplisav's treatments were effective, the FDA does not need to follow the advice of its committees. Dynavax's outlook remains positive, in Rama's view, and the FDA often goes along with its committees' recommendations.